https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-07-09 / Clin. Cancer Res. 2013 Sep;19(17):4801-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-07-09 / Clin. Cancer Res. 2013 Sep;19(17):4801-152013-07-09 00:00:002019-04-03 09:09:02A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-07-02 / Cancer Immunol. Immunother. 2013 Sep;62(9):1499-509
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-07-02 / Cancer Immunol. Immunother. 2013 Sep;62(9):1499-5092013-07-02 00:00:002019-02-15 08:46:28Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-07-02 / Biology (Basel) 2013 Jul;2(3):936-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-07-02 / Biology (Basel) 2013 Jul;2(3):936-752013-07-02 00:00:002021-11-15 16:56:11Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-24 / J. Clin. Invest. 2013 Jul;123(7):3135-45
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-24 / J. Clin. Invest. 2013 Jul;123(7):3135-452013-06-24 00:00:002019-02-15 08:48:46Melanoma immunotherapy using mature DCs expressing the constitutive proteasome
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-24 / Technol. Cancer Res. Treat. 2014 Apr;13(2):169-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-24 / Technol. Cancer Res. Treat. 2014 Apr;13(2):169-752013-06-24 00:00:002013-06-24 00:00:00Recombinant Newcastle disease virus Anhinga strain (NDV/Anh-EGFP) for hepatoma therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-21 / Cancer Treat. Rev. 2013 Dec;39(8):891-907
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-21 / Cancer Treat. Rev. 2013 Dec;39(8):891-9072013-06-21 00:00:002019-02-15 08:46:27Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-19 / Antioxid. Redox Signal. 2013 Dec;19(17):2141-56
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-19 / Antioxid. Redox Signal. 2013 Dec;19(17):2141-562013-06-19 00:00:002013-06-19 00:00:00Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-18 / J Transl Med 2013 Jun;11:149
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-18 / J Transl Med 2013 Jun;11:1492013-06-18 00:00:002019-02-15 08:52:12A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-04 / J Clin Oncol 31, 2013 (suppl; abstr e20042)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-04 / J Clin Oncol 31, 2013 (suppl; abstr e20042)2013-06-04 11:44:592019-07-17 11:45:20Biochemical and immunologic markers in patients with metastatic melanoma treated with chemotherapy and dendritic cell vaccine.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-04 / Oncol Lett 2013 Aug;6(2):537-541
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-04 / Oncol Lett 2013 Aug;6(2):537-5412013-06-04 00:00:002019-02-15 08:39:47Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients
